Several analysts have recently updated their ratings and price targets for Loxo Oncology (NASDAQ: LOXO):

  • 6/8/2017 – Loxo Oncology was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Loxo Oncology, Inc. is a biopharmaceutical company. It develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Loxo Oncology, Inc. is headquartered in Stamford, Connecticut. “
  • 6/6/2017 – Loxo Oncology had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $75.00 price target on the stock.
  • 6/5/2017 – Loxo Oncology was upgraded by analysts at Citigroup Inc. from a “neutral” rating to a “buy” rating. They now have a $86.00 price target on the stock.
  • 6/5/2017 – Loxo Oncology had its price target raised by analysts at Stifel Nicolaus from $52.00 to $71.00. They now have a “buy” rating on the stock.
  • 6/5/2017 – Loxo Oncology had its “outperform” rating reaffirmed by analysts at Cowen and Company.
  • 5/9/2017 – Loxo Oncology was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Loxo Oncology, Inc. is a biopharmaceutical company. It develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Loxo Oncology, Inc. is headquartered in Stamford, Connecticut. “
  • 5/3/2017 – Loxo Oncology was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $52.00 price target on the stock. According to Zacks, “Loxo Oncology, Inc. is a biopharmaceutical company. It develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Loxo Oncology, Inc. is headquartered in Stamford, Connecticut. “

Shares of Loxo Oncology, Inc. (LOXO) traded down 0.46% during trading on Friday, hitting $73.01. 249,125 shares of the company’s stock were exchanged. The firm has a 50-day moving average price of $52.78 and a 200-day moving average price of $42.70. Loxo Oncology, Inc. has a one year low of $17.14 and a one year high of $79.00. The stock’s market cap is $1.91 billion.

Loxo Oncology (NASDAQ:LOXO) last released its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.76) by $0.20. Equities research analysts expect that Loxo Oncology, Inc. will post ($4.22) EPS for the current fiscal year.

In other news, Director Keith T. Flaherty sold 7,250 shares of the company’s stock in a transaction on Monday, May 22nd. The shares were sold at an average price of $45.09, for a total value of $326,902.50. Following the sale, the director now directly owns 27,141 shares of the company’s stock, valued at approximately $1,223,787.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 44.40% of the stock is owned by corporate insiders.

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Receive News & Ratings for Loxo Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.